Ovid Therapeutics (OVID) Price Target Raised to $5 Due to Pipeline Progress

H.C. Wainwright has increased its price target for Ovid Therapeutics (OVID) to $5, citing advancements in the company's pipeline. This increase reflects investor confidence in Ovid's ongoing development efforts. The raised target may influence market perceptions and trading behavior related to Ovid Therapeutics. A higher price target can suggest potential for better future performance of the stock, which is significant for investors monitoring biotech firms.